ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Automated summary

There have been no major changes in practice in gastrointestinal oncology at the ESMO symposium 2021, but immunotherapy in combination with chemotherapy has been confirmed as the standard of care in several indications. The EORTC Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium for all gastrointestinal cancers, as well as early reports on new drugs or combinations that may change practice in the future.